{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:08:14Z","timestamp":1788822494405,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303807"],"award-info":[{"award-number":["82303807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172748"],"award-info":[{"award-number":["82172748"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013011"],"award-info":[{"award-number":["2024A1515013011"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012439"],"award-info":[{"award-number":["2021A1515012439"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Universities, Sun Yat-sen University","award":["24qnpy283"],"award-info":[{"award-number":["24qnpy283"]}]},{"name":"Young Talents Program of Sun Yat-sen University Cancer Center","award":["YTP-SYSUCC-0104"],"award-info":[{"award-number":["YTP-SYSUCC-0104"]}]},{"name":"Science and Technology Projects in Guangzhou","award":["2023A04J2131"],"award-info":[{"award-number":["2023A04J2131"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01489-9","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:05:02Z","timestamp":1779372302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Zengfei","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runduan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaozhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1489_CR1","first-page":"219","volume":"85","author":"G Kloppel","year":"2001","unstructured":"Kloppel, G. & Luttges, J. WHO-classification 2000: exocrine pancreatic tumors. Verh. Dtsch Ges. Pathol. 85, 219\u2013228 (2001).","journal-title":"Verh. Dtsch Ges. Pathol."},{"key":"1489_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10, 10\u201327 (2019).","journal-title":"World J. Oncol."},{"key":"1489_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1056\/NEJMc1107627","volume":"365","author":"V Vaccaro","year":"2011","unstructured":"Vaccaro, V., Sperduti, I. & Milella, M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 365, 768\u2013769 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1489_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1489_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/jco.2014.32.3_suppl.178","volume":"32","author":"D Goldstein","year":"2014","unstructured":"Goldstein, D. et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J. Clin. Oncol. 32, 178 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1489_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF00225544","volume":"186","author":"HD Dellmann","year":"1978","unstructured":"Dellmann, H. D. Scanning and transmission electron microscopy of the subfornical organ of the grass frog (Rana pipiens). Cell Tissue Res. 186, 361\u2013374 (1978).","journal-title":"Cell Tissue Res."},{"key":"1489_CR7","doi-asserted-by":"publisher","first-page":"e173420","DOI":"10.1001\/jamaoncol.2017.3420","volume":"4","author":"ZR Qian","year":"2018","unstructured":"Qian, Z. R. et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal Adenocarcinoma. JAMA Oncol. 4, e173420 (2018).","journal-title":"JAMA Oncol."},{"key":"1489_CR8","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","volume":"8","author":"Aguirre","year":"2018","unstructured":"Aguirre et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 8, 1096\u20131111 (2018).","journal-title":"Cancer Discov."},{"key":"1489_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRAS(G12C) Inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"1489_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann, M. H. et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 11, 142\u2013157 (2021).","journal-title":"Cancer Discov."},{"key":"1489_CR11","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1158\/1078-0432.CCR-04-0621","volume":"10","author":"MV Yezhelyev","year":"2004","unstructured":"Yezhelyev, M. V. et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 10, 8028\u20138036 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1489_CR12","first-page":"3551","volume":"58","author":"BB Flossmann-Kast","year":"1998","unstructured":"Flossmann-Kast, B. B., Jehle, P. M., Hoeflich, A., Adler, G. & Lutz, M. P. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res. 58, 3551\u20133554 (1998).","journal-title":"Cancer Res."},{"key":"1489_CR13","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.1158\/0008-5472.CAN-04-3858","volume":"65","author":"JG Trevino","year":"2005","unstructured":"Trevino, J. G. et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 65, 7214\u20137222 (2005).","journal-title":"Cancer Res."},{"key":"1489_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0919-5","volume":"17","author":"J Li","year":"2018","unstructured":"Li, J. et al. C-Src confers resistance to mitotic stress through inhibition DMAP1\/Bub3 complex formation in pancreatic cancer. Mol. Cancer 17, 174 (2018).","journal-title":"Mol. Cancer"},{"key":"1489_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl7895","volume":"15","author":"L Su","year":"2023","unstructured":"Su, L. et al. Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models. Sci. Transl. Med. 15, eabl7895 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1489_CR16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1158\/1078-0432.CCR-1183-3","volume":"10","author":"MS Duxbury","year":"2004","unstructured":"Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W. & Whang, E. E. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 10, 2307\u20132318 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1489_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1535-7163.MCT-14-0485","volume":"14","author":"Y Pan","year":"2015","unstructured":"Pan, Y. et al. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR\/Src\/VEGFR2, as a therapeutic agent against pancreatic cancer. Mol. Cancer Ther. 14, 407\u2013418 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1489_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon, S. Olverembatinib: First Approval. Drugs 82, 469\u2013475 (2022).","journal-title":"Drugs"},{"key":"1489_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13578-019-0351-6","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 9, 88 (2019).","journal-title":"Cell Biosci."},{"key":"1489_CR20","doi-asserted-by":"crossref","unstructured":"Qiu, H. et al. Updated efficacy results of olverembatinib (HQP1351) in patients \u00b1with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA). J. Clin. Oncol. 42, S1032 (2024).","DOI":"10.1016\/j.annonc.2024.08.1814"},{"key":"1489_CR21","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1158\/1535-7163.MCT-16-0225","volume":"15","author":"M Mattie","year":"2016","unstructured":"Mattie, M. et al. The discovery and preclinical development of ASG-5ME, an antibody-drug conjugate targeting SLC44A4-positive epithelial tumors including pancreatic and prostate cancer. Mol. Cancer Ther. 15, 2679\u20132687 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1489_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349\u2013361 (2012).","journal-title":"Cell"},{"key":"1489_CR23","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.1038\/sj.onc.1208161","volume":"23","author":"AB Reynolds","year":"2004","unstructured":"Reynolds, A. B. & Roczniak-Ferguson, A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 23, 7947\u20137956 (2004).","journal-title":"Oncogene"},{"key":"1489_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","volume":"18","author":"J Encarnacion-Rosado","year":"2021","unstructured":"Encarnacion-Rosado, J. & Kimmelman, A. C. Harnessing metabolic dependencies in pancreatic cancers. Nat. Rev. Gastroenterol. Hepatol. 18, 482\u2013492 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1489_CR25","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1038\/sj.onc.1205398","volume":"21","author":"SG Rane","year":"2002","unstructured":"Rane, S. G. & Reddy, E. P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21, 3334\u20133358 (2002).","journal-title":"Oncogene"},{"key":"1489_CR26","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-06-0456","volume":"12","author":"PM Siesser","year":"2006","unstructured":"Siesser, P. M. & Hanks, S. K. The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 12, 3233\u20133237 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1489_CR27","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/carcin\/bgn138","volume":"29","author":"A Kabil","year":"2008","unstructured":"Kabil, A., Silva, E. & Kortenkamp, A. Estrogens and genomic instability in human breast cancer cells-involvement of Src\/Raf\/Erk signaling in micronucleus formation by estrogenic chemicals. Carcinogenesis 29, 1862\u20131868 (2008).","journal-title":"Carcinogenesis"},{"key":"1489_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature13473","volume":"511","author":"S Walz","year":"2014","unstructured":"Walz, S. et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511, 483\u2013487 (2014).","journal-title":"Nature"},{"key":"1489_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1101\/gad.232082.113","volume":"28","author":"M Saborowski","year":"2014","unstructured":"Saborowski, M. et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 28, 85\u201397 (2014).","journal-title":"Genes Dev."},{"key":"1489_CR30","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-12-2067","volume":"73","author":"WC Lin","year":"2013","unstructured":"Lin, W. C. et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 73, 1821\u20131830 (2013).","journal-title":"Cancer Res."},{"key":"1489_CR31","doi-asserted-by":"crossref","unstructured":"Farrell, A. S. & Sears, R. C. MYC degradation. Cold Spring Harb. Perspect. Med. 4, a014365 (2014).","DOI":"10.1101\/cshperspect.a014365"},{"key":"1489_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ncb1110","volume":"6","author":"E Yeh","year":"2004","unstructured":"Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6, 308\u2013318 (2004).","journal-title":"Nat. Cell Biol."},{"key":"1489_CR33","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501\u20132514 (2000).","journal-title":"Genes Dev."},{"key":"1489_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785\u2013789 (1995).","journal-title":"Nature"},{"key":"1489_CR35","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/sj.onc.1210138","volume":"26","author":"RC Ishizawar","year":"2007","unstructured":"Ishizawar, R. C., Miyake, T. & Parsons, S. J. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 26, 3503\u20133510 (2007).","journal-title":"Oncogene"},{"key":"1489_CR36","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/j.1460-2075.1993.tb05879.x","volume":"12","author":"S Mori","year":"1993","unstructured":"Mori, S. et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. 12, 2257\u20132264 (1993).","journal-title":"EMBO J."},{"key":"1489_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0092-8674(90)90013-5","volume":"62","author":"RM Kypta","year":"1990","unstructured":"Kypta, R. M., Goldberg, Y., Ulug, E. T. & Courtneidge, S. A. Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 62, 481\u2013492 (1990).","journal-title":"Cell"},{"key":"1489_CR38","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1002\/j.1460-2075.1996.tb00915.x","volume":"15","author":"K Hansen","year":"1996","unstructured":"Hansen, K. et al. Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 15, 5299\u20135313 (1996).","journal-title":"EMBO J."},{"key":"1489_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503\u2013514 (2012).","journal-title":"Immunity"},{"key":"1489_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"1489_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13046-025-03513-5","volume":"44","author":"Y Niu","year":"2025","unstructured":"Niu, Y. et al. TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity.J. Exp. Clin. Cancer Res.44, 242 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1489_CR42","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1489_CR43","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","volume":"49","author":"A Luna","year":"2021","unstructured":"Luna, A. et al. CellMiner Cross-Database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Res. 49, D1083 D1093 (2021).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01489-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:34:14Z","timestamp":1788820454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01489-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01489-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"347"}}